Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026

Phase 2positiveBW-20805Positive

AI Analysis

Summary

Argo Biopharma announced updated positive Phase II results for siRNA therapeutic BW-20805 in hereditary angioedema, to be presented at the Bradykinin Symposium 2026.

Clinical Trial Data

Phase

Phase II

Outcome Details

Updated Phase II results to be presented

Importance:6/10

Sentiment:

0.70

siRNAPhase IIHereditary AngioedemaArgo BiopharmaBradykinin Symposium

Read the original article

Published by PR Newswire Pharma on September 4, 2026 6:00 AM

Read Original